COVID-19 home antibody testing study

Serological testing for COVID-19 in ALSPAC (G0/G1)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN53701620

Enrollment

7000

Registered

2023-08-08

Start date

2020-09-16

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 home antibody testing study Infections and Infestations

Interventions

Our outcome measure is lateral flow test derived evidence of positive antibody response to COVID-19 given knowledge of the sensitivity and specificity of the Fortress Home Test kit. This is relevant g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible participants in ALSPAC, a longitudinal study

Exclusion criteria

Exclusion criteria: 1. Any participant who responded ‘No’ to the question that asked if they would be happy for the study team to send information about research involving testing for COVID-19 in the ‘Learning more about COVID-19’ questionnaire 2. Increased risk of bleeding (participants will be asked at the consenting stage to self-declare any issues related to bleeding disorders) 3. Participants outside the UK. Costs and timescales for postage outside the UK make this impractical. 4. Participants who are flagged as deceased, withdrawn, no to questionnaires and no to contact.

Design outcomes

Primary

Measure	Time frame
Covid 19 infection status measured using a COVID-19 home antibody test at one timepoint	—

Secondary

Measure	Time frame
The are no secondary outcome measures	—

Countries

England, United Kingdom

Contacts

Public ContactPaul Hazell

Paul.hazell@bristol.ac.uk+44 (0)117 4553686

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026